Epidemiological and Clinical Description of Women Living With HIV in Selected Countries of Latin America

Hiv Clinical Trial

Official title:

Epidemiological and Clinical Description of Women Living With HIV in Selected Countries of Latin America

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04605354
• Other study ID #: Women living with HIV in LATAM
• Status: Enrolling by invitation
• Start date: July 1, 2020
• Est. completion date: January 1, 2022

Study information

• Verified date: October 2020
• Source: Helios Salud
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A cross-sectional study that uses ecological data from (1) PLWHIV under care at 31st December 2017, and (2) from yearly admissions to care occurred during 2013 - 2017, from centers belonging to LAW-HIV.

Description:

General Aims Aim 1: Epidemiological and clinical description of women that receive HIV care in selected countries of Latin America.

Aim 2: Management of HIV infection during pregnancy in women from selected countries of Latin America.

Countries: Argentina, Bolivia, Chile, Colombia, Costa Rica,Ecuador, Guatemala, Honduras, México, Peru, Dominican, Republic, Uruguay, and Venezuela.

Background & Relevance of this specific study:

Research Approach:

The Latin American Workshop for HIV Studies (LAW-HIV) includes more than 70 clinical centers belonging to 14 Spanish speaking countries from the region. It gathers aggregate information form more than 116.000 people living with HIV under care, from which 25,802 are women.

These numbers represent roughly a fifth of the total estimated female under care in these countries.

Specific aims from overall aim 1:

The investigators will determine at center, national and regional level:

• The age distribution of women under care for HIV infection as of December 31st, 2017.

• The fraction of women under care who are receiving ART as of December 31st, 2017.

• The age distribution of women admitted to care for years 2013, 2014, 2015, 2016 and 2017.

• The fraction of admitted women that start ART during the first year after admission, by year of admission.

• Frequency of selected type of drugs (for backbone and 3rd drug) used for the first cART, by year of admission and age group.

• The frequency late and very late presenters (CD4) in women admitted according to year of admission and age group.

• The fraction of women alive, retained to care, retained to ART, and with virologic suppression at one year of follow up, from admissions occurred in 2016.

Specific aims from overall aim 2:

The investigators will determine:

• The fraction of women with HIV diagnosis occurred as consequence of the pregnancy.

• Earliest CD4 level and viral load in pregnant women under care by HIV.

• The fraction of women that suspend ART during pregnancy; frequency of each scheme of ART used previous the conception; and change of scheme (3rd drug and backbone).

• The fraction of women whose pregnancy ended in term, preterm or as abortion.

• The fraction of women retained in control post pregnancy.

• The fraction of women that suspended breastfeeding Data Collection & Quality:

Study Design:

A cross-sectional study that uses ecological data from (1) People living with HIV under care at 31st December 2017, and (2) from yearly admissions to care occurred during 2013 - 2017, from centers belonging to LAW-HIV. Data will be weighted by the expected population under care in each country considering attributes of the centers (private/public). Weighted outcomes at strata level from each center will be meta-analyzed considering three levels of heterogeneity (stratum, center, and country) and modeled through multilevel regression models to allow adjustment for covariables of the stratum. In the case of admissions to care, a time series analysis will be implemented.

Data collection and quality control:

Data collection will be carried out through a spreadsheet sent to centers that agree to participate. Two different spreadsheets will be sent, one for each general aim of the study (see the annex at the complete project). A quality check will be implemented at three stages: (1) at the moment of receiving each spreadsheet back; (2) previous to analysis, where the consistency of information across strata from different sections will be assessed; and (3) identifying outlier values from outcomes at the centers level, using expert criteria.

Data information included:

1. Center description (health care staff, ART & labs (e.g. viral load determinations) availability)

2. Demographic and clinical features of women under control and admitted (age, CD4, the scheme of ART, retention to care, retention to ART, virologic suppression one year later the admission).

3. Clinical features of pregnant women under care infected by HIV.

Total duration: 18 months.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 25816
• Est. completion date: January 1, 2022
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

• All Latin American HIV care centers from any Spanish speaking country are invited to participate in the LAW-HIV.

• Only centers that provide a minimum of information (at least sections 1 and 2 from the datasheet for aim 1) will be included in the analysis

Related Conditions & MeSH terms

• Hiv
• HIV-1-infection

Locations

Country	Name	City	State
Argentina	Helios Salud	Buenos Aires

Sponsors (2)

Lead Sponsor	Collaborator
Helios Salud	ViiV Healthcare

Country where clinical trial is conducted

Argentina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Epidemiological and clinical description of women that receive HIV care in selected countries of Latin America.	1.1. In women admitted to care between years 2013-2017, the trend in the: distribution of ages; proportion of late presenters (CD4).; proportion that start ART during the first year after admission; schemes of ART used for the first ART.; 1.2. Proportion of women alive, retained to care, retained to ART, and with virologic suppression at one year of follow up, from admissions occurred in 2016.	1 year
Primary	Management of HIV infection during pregnancy in women from selected countries of Latin America.	2. In women that finished their pregnancy at any moment during 2019: Proportion with HIV diagnosis as consequence of the pregnancy.; Earliest CD4 level.; Proportion that suspended ART during pregnancy; Frequency of each scheme of ART used previous the conception; Change of scheme of ART; Proportion whose pregnancy ended in term; Proportion retained in care during the first 6 months after pregnancy; Proportion that suspended breastfeeding during the first 3 months after pregnancy	1 year